Idexx Laboratories financials
$533.44+0.83%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B | $2.71B | $2.41B | $2.21B | $1.97B | $1.78B |
| Gross profit | $2.66B | $2.38B | $2.19B | $2.00B | $1.89B | $1.57B | $1.37B | $1.24B | $1.10B | $975.4M |
| Gross margin | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% |
| Operating income | $1.36B | $1.13B | $1.10B | $898.8M | $932.0M | $694.5M | $552.8M | $491.3M | $413.0M | $350.2M |
| Net income | $1.06B | $887.9M | $845.0M | $679.1M | $744.8M | $581.8M | $427.7M | $377.0M | $263.1M | $222.0M |
| Net margin | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
| Diluted EPS | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 | $6.71 | $4.89 | $4.26 | $2.94 | $2.44 |
| EBITDA | $1.51B | $1.26B | $1.21B | $1.01B | $1.04B | $790.5M | $640.9M | $574.5M | $496.2M | $428.5M |
| Operating cash flow | $1.18B | $929.0M | $906.5M | $543.0M | $755.5M | $648.1M | $459.2M | $400.1M | $373.3M | $338.9M |
| Free cash flow | $1.06B | $808.1M | $772.9M | $394.1M | $636.0M | $541.1M | $304.2M | $284.3M | $298.9M | $274.2M |
| Diluted shares | 81.0M | 83.2M | 84.0M | 84.6M | 86.6M | 86.7M | 87.5M | 88.5M | 89.6M | 90.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $180.1M | $288.3M | $453.9M | $112.5M | $144.5M | $383.9M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $847.8M | $867.6M | $947.9M | $1.35B | $923.7M | $908.5M |
| Total assets | $3.35B | $3.29B | $3.26B | $2.75B | $2.44B | $2.29B |
| Total liabilities | $1.75B | $1.70B | $1.78B | $2.14B | $1.75B | $1.66B |
| Shareholders' equity | $1.61B | $1.60B | $1.48B | $608.7M | $690.0M | $632.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology